By Roshan Fernandez
Rafael Holdings said Chief Executive Bill Conkling will be stepping down from his role following the clinical and early-stage pharmaceutical company's merger with Cyclo Therapeutics.
Conkling's departure is effective May 31. Rafael's executive chairman and former CEO, Howard Jonas, will assume the role of CEO at the Newark, N.J.-based company, effective June 1.
Conkling, who has been CEO since 2022, helped identify opportunities with the potential to transform Rafael into a late-stage clinical biotechnology company. Rafael completed its merger with Cyclo on March 26.
Jonas, 68 years old, has served as chairman of the board since 2017. He was also previously CEO from March 2018 through April 2021.
Write to Roshan Fernandez at roshan.fernandez@wsj.com
(END) Dow Jones Newswires
April 24, 2025 17:33 ET (21:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.